Created at 5:14 a.m. Oct, 20, 2025
Author: mohannadkh10
Related Note: 1484950433581 1
Rationale for change

I don’t believe naltrexone is FDA-approved for nicotine dependence or smoking cessation.

The FDA-approved and first-line pharmacologic treatments for smoking cessation are:
1- Varenicline (nicotine receptor partial agonist)
2- Bupropion (norepinephrine-dopamine reuptake inhibitor)
3- Nicotine replacement therapy (NRT) (e.g., patch, gum, lozenge, inhaler, nasal spray)

Including naltrexone in this context may create unnecessary confusion, as it is not part of standard treatment protocols for smoking cessation.

Amboss: https://next.amboss.com/us/article/mr0V3h?q=varenicline#FJ1gD30

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#Pixorize::03_Pharmacology::17_Psych_Pharm::19_Naltrexone #AK_Step1_v12::#Pixorize::03_Pharmacology::16_Other_Neuro_Pharm::22_Naltrexone #AK_Step2_v12::#B&B::13_Psych::03_Substance_Abuse::01_Alcohol_Use_Disorder #AK_Step2_v12::#SketchyPsych::10_Substance_Use/_Medication_Related_Disorders::01_Substance_Use_Overview #AK_Step2_v12::#UWorld::Step::12541 #AK_Step1_v12::#Physeo::09_Pharm::13_Psychiatric::05_Alcohol #AK_Step1_v12::#Physeo::09_Pharm::13_Psychiatric::06_CNS_Stimulants_Overview #AK_Step1_v12::#Bootcamp::Psychiatry::08_Substance_Misuse::01_Alcohol #AK_Step1_v12::#Pixorize::03_Pharmacology::16_Other_Neuro_Pharm::21_Naloxone #AK_Step1_v12::^Systems::Neuro::Pharmacology #AK_Step2_v12::#CMS::Psychiatry::Form_05 #AK_Step1_v12::#UWorld::Step::11577 #AK_Step1_v12::#Physeo::09_Pharm::14_Neuro::21_Opioid_Clinical_Use,_Mechanism_and_Overdose #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#UWorld::COMLEX::25555 #AK_Step1_v12::#Physeo::09_Pharm::13_Psychiatric::10_Nicotine #AK_Step1_v12::#FirstAid::13_Psych::03_Pharm::13_Medically_supervised_opioid_withdrawal_and_relapse_prevention::04_Naltrexone #AK_Step1_v12::#B&B::19_Psych::03_Substance_Use_Disorders::02_Opioids::Extra #PANCE::BEHAVIORAL::substance_use #AK_Step2_v12::#NBME #PANCE::EOR::PSYCH #AK_Step1_v12::#Pixorize::03_Pharmacology::16_Other_Neuro_Pharm::17_Full_Opioid_Agonists #AK_Step1_v12::#FirstAid::13_Psych::03_Pharm::13_Medically_supervised_opioid_withdrawal_and_relapse_prevention #AK_Step1_v12::#B&B::19_Psych::03_Substance_Use_Disorders::01_Alcohol_and_CNS_Depressants #AK_Step1_v12::#Physeo::09_Pharm::13_Psychiatric::30_Opioid_Withdrawal,_Detoxification_and_Relapse_Prevention #AK_Step1_v12::#OME::Clinical::Pediatrics/Psychiatry #AK_Step2_v12::#UWorld::COMLEX::102328 #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#SketchyPharm::06_Neuro_&_Psych::01_Anesthetics_&_Analgesics::03_Opiates,_Naloxone,_Naltrexone #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step1_v12::#Bootcamp::Psychiatry::08_Substance_Misuse::04_Opioid_Classification #AK_Other::Only_Step_1&2_Overlap #AK_Step1_v12::#Pixorize::^Missing_image #AK_Step2_v12::!Shelf::EM